Related Experiment Video

Updated: Aug 14, 2026

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Refractory Hodgkin lymphoma responds to pentostatin (2'-deoxycoformycin)

Fadi Braiteh, Chaan Ng, Razelle Kurzrock

    Leukemia & Lymphoma
    |December 3, 2005
    PubMed
    Abstract

    No abstract available in PubMed .

    Related Experiment Videos

    Last Updated: Aug 14, 2026

    Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
    09:02

    Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

    Published on: July 31, 2016

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    Approach to the patient with metastatic pheochromocytoma and paraganglioma: advances in systemic therapy.

    The Journal of clinical endocrinology and metabolism·2026

    Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial.

    Nature medicine·2025

    Multi-Institutional, Prospective Clinical Utility Study Evaluating the Impact of the 92-Gene Assay (CancerTYPE ID) on Final Diagnosis and Treatment Planning in Patients With Metastatic Cancer With an Unknown or Unclear Diagnosis.

    JCO precision oncology·2022

    Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2021

    Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration.

    Targeted oncology·2021

    Author response to Cunha et al.

    Journal for immunotherapy of cancer·2021

    Incidence of clinically significant chemotherapy induced nausea and vomiting with brentuximab vedotin and AVD in comparison with ABVD using standard anti-emetic prophylaxis.

    Leukemia & lymphoma·2026

    The roles of RUNX1 in megakaryocyte differentiation in myeloid leukemia.

    Leukemia & lymphoma·2026

    Prognostic factors of 10-year survival in patients with myeloma after autologous stem cell transplantation: a multicenter retrospective analysis.

    Leukemia & lymphoma·2026

    Evaluation of hypomethylating agents with or without venetoclax in patients with accelerated phase and blast phase myeloproliferative neoplasms: a HERO consortium study.

    Leukemia & lymphoma·2026

    Soluble PD-L1 as prognostic biomarker in acute myeloid leukemia.

    Leukemia & lymphoma·2026

    Dose optimization of single-agent inotuzumab ozogamicin in adults with relapsed/refractory acute lymphoblastic leukemia.

    Leukemia & lymphoma·2026

    The Timing and Characteristics of Supplemental Indications for Medicines.

    The American journal of managed care·2026

    New-onset alopecia areata during calcitonin gene-related peptide inhibitor therapy: first reported case.

    Dermatology reports·2026

    Therapeutic effect of Fuzheng Yixin decoction on cardiac insufficiencythe soluble guanylyl cyclase-cyclic guanosine monophosphate-protein kinase G pathway in a doxorubicin-induced dilated cardiomyopathy rat model.

    Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan·2026

    Shaofu Zhuyu decoction can inhibit the progression of endometriosis fibrosis through the transforming growth factor-β1/ smads signaling pathway mediated by 5' adenosine monophosphate-activated protein kinase.

    Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan·2026

    Baihe Dihuang decoction activates cannabinoid type 2 receptor to regulate microglial polarization and alleviate anxiety-like behavior in chronic restraint stress mice.

    Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan·2026

    Real-World Treatment Patterns and Clinical Outcomes with Cyclosporine 0.1% in Semifluorinated Alkane for Dry Eye Disease.

    Clinical ophthalmology (Auckland, N.Z.)·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us